In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.
With inoperable advanced malignant solid tumors, including melanoma, gastrointestinal tumor, breast cancer, pancreatic cancer, cervical cancer, lung cancer, etc.
Failed in standard treatment or voluntarily give up other treatment, and been longer than 2 weeks from the end of the last anti-tumor treatment
Had disease progression prior to treatment
Expected survival ≥ 3 months
Pregnant or breastfeeding women
Patients with brain metastases
Had immunosuppressant therapy within 1 month or received other immunotherapy within 3 months
Participated in other clinical study within 30 days
The First Affiliated Hospital of Nanchang University
Lead sponsor
Shanghai Dengding BioAI Co.
Collaborator